表皮生长因子受体在一部分急性髓系白血病中表达并具有活性。
Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia.
作者信息
Mahmud Hasan, Kornblau Steven M, Ter Elst Arja, Scherpen Frank J G, Qiu Yi Hua, Coombes Kevin R, de Bont Eveline S J M
机构信息
Department of Pediatrics, Division of Pediatric Oncology/Hematology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
出版信息
J Hematol Oncol. 2016 Aug 3;9(1):64. doi: 10.1186/s13045-016-0294-x.
The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for a role of EGFR in AML whereas a recent phase II clinical study with gefitinib in AML demonstrated a negative result on the outcome. However, from several studies, EGFR expression in AML is poorly defined and the role of EGFR in AML remains unclear. Herein, we report the results of EGFR expression in AML of large cohorts of adult and pediatric AML patients with the data of total protein and phosphorylation levels of EGFR. Our data conclude that there is the expression of EGFR at the protein level in a subset of AML, which was identified to be functionally active in ~15 % of AML patients. This suggests that future studies need to be conducted with a subset of AML patients characterized by high EGFR expression.
表皮生长因子受体（EGFR）抑制剂厄洛替尼已被证明可使两名同时患有肺癌的急性髓系白血病（AML）患者实现完全缓解，这引起了人们对EGFR在AML中作用的关注，而最近一项吉非替尼治疗AML的II期临床研究结果显示为阴性。然而，多项研究表明，AML中EGFR的表达情况尚不明确，其在AML中的作用仍不清楚。在此，我们报告了大量成人和儿童AML患者队列中EGFR表达的结果，以及EGFR总蛋白和磷酸化水平的数据。我们的数据表明，一部分AML患者在蛋白水平存在EGFR表达，其中约15%的AML患者被确定具有功能活性。这表明未来需要针对具有高EGFR表达特征的一部分AML患者开展研究。
Zotero 插件